ENTA
Enanta Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Enanta Pharmaceuticals, Inc. (ENTA) closed at $12.51 as of 2026-03-20, trading 40.0% below its 200-week moving average of $20.86. This places ENTA in the extreme value zone. The stock is currently moving closer to the line, down from -39.5% last week. The 14-week RSI sits at 40, indicating neutral momentum.
Trading volume is running at 0.8x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.26 ratio) is neutral — neither side is clearly dominating.
Over the past 630 weeks of data, ENTA has crossed below its 200-week moving average 8 times. On average, these episodes lasted 47 weeks. Historically, investors who bought ENTA at the start of these episodes saw an average one-year return of +3.1%.
With a market cap of $363 million, ENTA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -60.0%. The stock trades at 2.9x book value.
Share count has increased 2.9% over three years, indicating dilution.
Over the past 12.2 years, a hypothetical investment of $100 in ENTA would have grown to $34, compared to $429 for the S&P 500. ENTA has returned -8.5% annualized vs 12.7% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ENTA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ENTA Crosses Below the Line?
Across 8 historical episodes, buying ENTA when it crossed below its 200-week moving average produced an average return of -5.1% after 12 months (median -14.0%), compared to +6.1% for the S&P 500 over the same periods. 12% of those episodes were profitable after one year. After 24 months, the average return was +7.0% vs +29.5% for the index.
Each line shows $100 invested at the moment ENTA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ENTA has crossed below its 200-week MA 8 times with an average 1-year return of +3.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2015 | Apr 2015 | 2 | 3.9% | -13.8% | -60.1% |
| Oct 2015 | Dec 2016 | 59 | 32.4% | +2.5% | -47.9% |
| Feb 2017 | Jun 2017 | 18 | 14.1% | +145.3% | -58.2% |
| Jan 2020 | Oct 2021 | 91 | 37.7% | -22.5% | -78.7% |
| Jan 2022 | Feb 2022 | 6 | 16.6% | -14.2% | -79.1% |
| Mar 2022 | Mar 2022 | 1 | 2.8% | -30.6% | -80.8% |
| Apr 2022 | Aug 2022 | 14 | 38.4% | -44.8% | -80.6% |
| Sep 2022 | Ongoing | 184+ | 86.3% | Ongoing | -77.6% |
| Average | 47 | — | +3.1% | — |
Frequently Asked Questions
Is ENTA below its 200-week moving average?
Yes. As of 2026-03-20, Enanta Pharmaceuticals, Inc. (ENTA) is trading 40.0% below its 200-week moving average of $20.86. The current price is $12.51.
What is ENTA's 200-week moving average price?
Enanta Pharmaceuticals, Inc.'s 200-week moving average is $20.86 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ENTA drops below its 200-week moving average?
ENTA has crossed below its 200-week moving average 8 times in our data. On average, buying at that moment produced a one-year return of +3.1%. These dips have historically been decent entry points. These episodes lasted 47 weeks on average.
Is ENTA a good value right now?
Here's what our data says about ENTA as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 40. Free cash flow is currently negative. Return on equity is -60.0%. Price-to-book is 2.9x. This is not a buy or sell recommendation — always do your own research.
How does ENTA compare to the S&P 500?
Over the past 12.2 years, $100 invested in ENTA would have grown to $34, compared to $429 for the S&P 500. That's -8.5% annualized vs 12.7% for the index. ENTA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20